Status:
COMPLETED
Parkinson's Disease Evaluated by PET and the Effect of Memantine
Lead Sponsor:
University of Aarhus
Collaborating Sponsors:
Lundbeck Foundation
Conditions:
Parkinson's Disease
Eligibility:
All Genders
50-70 years
Phase:
NA
Brief Summary
Purpose of study: To investigate whether the NMDA antagonist Memantine has a substantial effect of brain metabolism in patients with Parkinson's disease (PD), using Positron Emission Tomography (PET)....
Eligibility Criteria
Inclusion
- Parkinson's Disease (British Brain Bank Criteria)
- Age 50-70y
Exclusion
- Tobacco use
- Any serious medical conditions (Heart disease, kidney disease, liver disease, endocrinological disorders etc)
- Metal implants contraindicating MR scan
- Drug use affecting the central nervous system
- Psychiatric disorders
- Head trauma or any disorders of the head, skull or brain
- Drug addiction or use of any kind of illegal substance affecting the central nervous system
- Pregnancy
Key Trial Info
Start Date :
April 1 2005
Trial Type :
INTERVENTIONAL
End Date :
September 1 2006
Estimated Enrollment :
12 Patients enrolled
Trial Details
Trial ID
NCT00375778
Start Date
April 1 2005
End Date
September 1 2006
Last Update
September 13 2006
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
PET center, Aarhus University Hospital
Aarhus, Denmark, 8000